Mumbai, Dec 29 :    Mumbai, Dec 29:  Glaxo India Ltd, today sold its liver tonic Livogen to E. Merck India for a consideration of Rs 8 crore. The sale of Livogen forms part of a rationalisation exercise within its product portfolio that entails withdrawal from tail-end brands. While the deal was announced late last month, Glaxo said the sale includes the rights, title and interest in the registered trademark of Livogen. Glaxo, it may be recalled, had announced that it would sell its its tail-end brands over the next couple of years and the proceeds from the disposal of these brands would be invested in additional promotion of new products. Meanwhile, the Glaxo scrip witnessed a roller-coaster ride when it finished at Rs 454.45 after opening at Rs 457 and rising to an intra-day high of Rs 460. The counter witnessed 42,820 trades, generating a total turnover of Rs 1.95 crore. The E Merck scrip closed higher at Rs 432.60 after opening at Rs 431.50 and rising to an intra-day high of Rs 435. Earlier, Glaxo had sold its haemorrhoids ointment brand Anovate and skin ointment brand Derobin to US Vitamins for Rs 6 crore. The company had also sold Macraberin and Multivite FM to Universal Medicare fo Rs 10 crore.